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Since first encountered, it has been clear that whilst many patients with COVID-19 experience 
relatively minor symptoms, some develop more serious disease.1-2 Studies have suggested that 
oncology patients, including haematological malignancies, have increased risk of severe 
COVID-19 disease with increased morbidity and mortality.3-5 
This retrospective study, conducted by clinicians and researchers from nine West Midlands 
hospitals, included all adult patients with both an underlying haematological disorder and 
confirmed COVID-19, diagnosed between 01/03/2020 and 31/05/2020. A standardised data 
collection form collected demographic, clinical, laboratory, radiological and outcome data. 
SARS-Cov-2 was diagnosed by RT-PCR. Ethical clearance waiver for the audit was received 
from all hospitals. 
Patients were categorized based upon their underlying haematological conditions; those on 
active chemotherapy, having relapsed and or refractory disease, acute myeloid leukaemia with 
adverse cytogenetics, post auto or allogeneic transplant, extranodal T-cell lymphoma, multiple 
myeloma, post splenectomy and sickle cell disease were classified high risk. Intermediate risk 
included Hodgkin’s and non-Hodgkin’s lymphoma patients not on any treatment, 
myeloproliferative neoplasms and myelodysplastic syndrome. The low risk cohort were 
patients with non-malignant haematological conditions and patients in complete remission 
having completed treatment >6months ago, adapted from the 2012 categorisation by Armand.6 
Severe COVID-19 infection was classified on the presence of any one of: oxygen saturation 
≤90% on room air, respiratory rate ≥24 breaths per minute; and/or bilateral infiltrates on lung 
imaging as defined in WHO guidelines.7  
Statistical analysis used IBM SPSS® version 26 and STATA SE®16. Kruskal–Wallis tests 
compared observations for the hazard event, i.e. survival and non-survival. For testing of three 
groups, the ANOVA-one-way-test, coupled with the Tukey-post-test was utilized. Using 
logistic regression and the Cox-proportional hazards model, the impact, and the survival 
estimates of these various factors, was studied. 
The median age was 70 years [IQR 61,78; range 18,95]. Men (57.5%) were the majority 
compared to women (41.5%). Regarding ethnicity, 76% of patients were Caucasian. There 
were 82% of patients with a malignant haematological disorder whilst 18% had non-malignant 
conditions. The commonest co-morbidities in this study cohort were hypertension (41%), 
ischaemic heart disease (22%), diabetes mellitus (21%), chronic lung disease (20%) and 
obesity (10%), and 30% had no documented co-morbidity. The most common symptoms 
experienced on admission were shortness of breath (58%), cough (43%) and fever (33%). Only 
4.4% of patients were asymptomatic and 63% of patients had severe COVID-19 symptoms at 
presentation. The UK government COVID-19 data (coronavirus.data.gov.uk) on 19/6/2020 
reported 300,469 confirmed COVID-19 cases and 42,285 deaths, indicating 14% mortality for 
all infections and 30% for hospitalised patients. Our mortality was 55% (RR 1.8).  
Chest x-ray findings (p=0.002), pulmonary infiltrates on computerised tomography (CT) scan 
(p=0.023), age (p=0.032) and obesity (odd’s ratio: 2.34) were independent variables and 
significant predictors of mortality. Risk factors identified in other series such as diabetes or 
hypertension or ethnicity, were not associated with an adverse outcome in this cohort. Our 
study finds that low oxygen saturation (p =0 015), increased respiratory rate (p=0.001) and 
high C-reactive protein (p=0.073) were statistically significant predictors of mortality. Other 
factors that were statistically significant includes breathlessness (p=0.011), confirmatory CT 
of pulmonary infiltrates (p=0.27) and patients showing abnormal finding on x-ray (p=0.003). 
The details are provided in the supplement. A multivariate analysis examined the odds ratio of 
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the various significant factors (Table I). 
 
Table I: Predictive Analysis on in-hospital mortality on multivariate model 
Variables Odds Ratio Std. Err.  
Breathlessness 2.28 0.735** (0.010) 
 
Obesity 2.34 0.027* (0.058) 
 






Respiratory Rate 1.03 0.010*** (0.002) 
 
COVID-19 Severity 1.95 0.493*** (0.008) 
 
Pulmonary Infiltrates (CT) 1.68 0.397** (0.026) 
 
Chest imaging positivea 1.04 0.027* (0.078) 
 
APTT 1.02 0.012** (0.016) 
 
Fibrinogen 1.12 0.076* (0.086) 
 
Interaction Variables:    
COVID-19 Severity and Malignancy 1.58 0.414* (0.079) 
 
COVID-19 Severity and High Risk Group 2.14 0.697** (0.019) 
 
COVID-19 Severity and Age 2.00 0.778* (0.075) 
 
Age and High Risk Group   2.13 0.915* (0.080) 
 
 
Note: *** indicates significant at 1 percent level, ** indicates significant at 5 percent level and * indicates 
significance at 10 percent level. The p-values are provided in parenthesis. 
a Positive i.e. abnormal finding on x-ray 
 
Our model included several interaction variables that significantly affected COVID-19 
mortality. Amongst the variables concerned, COVID-19 severity and haematology disease-
based risk profile had greatest impact. Using logistic regression and a predictive marginal 
model, factors affecting mortality were examined. An odds ratio >1 indicated that the variable 
had a positive impact on death. COVID-19 severity had greatest impact on mortality. While 
COVID-19 severity and increase age increased the chance of death, by 24% and 15%, 
respectively, non-malignancy reduced the mortality. Of interest, obesity negatively impacted 
survival. 
Using logistic regression and the Cox-proportional hazards model, the impact and survival 
estimates were examined. Figure I show that the severity of COVID-19 significantly impacted 
patients with malignant haematological conditions (75 % survival probability, the survival was 
8 days as compared to 19 between severe & non-severe patients). Additionally, haematological 
disease-based risk status was significant for COVID-19 mortality (mean survival 7 days in the 




Figure I: COVID-19 Severity and Malignancy  
 
Note: Figure 1 shows the graph of the survival functions. The X-axis represents the Analysis Time, which is the 
duration in days between the dates of onset of COVID-19 symptoms and death. 
This is the largest series of patients yet reported with haematological conditions infected by 
SARS-Cov-2. These patients may present with COVID-19 differently. Fever was observed in 
33% of our patient cohort as compared to 71% in the Clinical Characterisation Protocol UK 
(CCP-UK) study.8As in previous reports in the general population and specific blood cancers, 
older age was associated with higher mortality in this cohort. However other co-morbidities 
like diabetes or hypertension did not confer adverse outcome.9 Overall mortality was 55%. This 
higher mortality could be due to this cohort, or that the West Midlands was the second most-
affected region in the country. Atypical presentation, particularly the lower proportion with 
fever (33%) as highlighted in our series may have caused delay in patients seeking medical 
attention. This underlines the importance of close attention to inflammatory markers and 
identifying signs of developing coagulopathy.10 Limitations result from collection at the height 
of the pandemic workload, where not all data parameters were collected for every patient. 
Additionally, only hospital managed patients’ outcomes are reported.  
The presence of lung infiltrates and other underlying lung pathology denotes a particularly 
high-risk group. Contrary to expectations, this cohort highlights that being on systemic 
chemotherapy did not increase risk of mortality. This suggests primary therapy for the 
haematological condition could be continued to avoid adverse impact on their underlying 
haematological condition.  
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